A Caucasian man peers into the cracked glass of an aquarium that has water pouring out from two places. The headline reads, “Discover Resources“.A Caucasian man peers into the cracked glass of an aquarium that has water pouring out from two places. The headline reads, “Discover Resources“.

Resources
For IgA
Nephropathy
And FSGS

Choose a topic below to access related resources.

Topics
(Select all that apply)
Filter by
(Select all that apply)

Treatment guidelines

Illustration of a stack of pages with one corner turned down.

Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-S276.

Illustration of a stack of pages with one corner turned down.

Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753-779. doi:10.1016/j.kint.2021.05.015.

Illustration of a calculator.

IgAN Risk Prediction Tool (Adults)a

aThe International IgAN Prediction Tool incorporates clinical information at the time of biopsy and additional research is needed to determine if the output can be used at other time points in the progression of the disease. This tool cannot be used to determine the likely impact of any particular treatment regimen.1,2

Illustration of a calculator.

IgAN Risk Prediction Tool (Pediatrics)a

aThe International IgAN Prediction Tool incorporates clinical information at the time of biopsy and additional research is needed to determine if the output can be used at other time points in the progression of the disease. This tool cannot be used to determine the likely impact of any particular treatment regimen.1,2

Endothelin-1 & angiotensin II

Illustration of a stack of pages with one corner turned down.

Komers R & Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R877-R884.

Illustration of a stack of pages with one corner turned down.

Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014;86(5):896-904.

Illustration of a stack of pages with one corner turned down.

van de Lest NA, Bakker AE, Dijkstra KL, et al. Endothelial endothelin receptor A expression is associated with podocyte injury and oxidative stress in patients with focal segmental glomerulosclerosis. Kidney Int Reports. 2021;6(7):1939-1948. doi:10.1016/j.ekir.2021.04.013.

Illustration of a stack of pages with one corner turned down.

Lehrke I, Waldherr R, Ritz E, et al. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol. 2001;12(11):2321-2329.

Illustration of a stack of pages with one corner turned down.

Dhaun N, Webb DJ, Kluth DC. Endothelin-1 and the kidney–beyond BP. Br J Pharmacol. 2012;167(4):720-731.

FSGS & proteinuria

Illustration of a stack of pages with one corner turned down.

Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017;12(3):502-517.

Illustration of a stack of pages with one corner turned down.

Jefferson JA, Shankland SJ. The pathogenesis of focal segmental glomerulosclerosis. Adv Chronic Kidney Dis. 2014; 21(5):408-416.

Illustration of a stack of pages with one corner turned down.

Troyanov S, Wall CA, Miller JA, et al; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005;16(4):1061-1068.

Illustration of a stack of pages with one corner turned down.

Troost J, Trachtman H, Nachman PH, et al. An outcomes-based definition of proteinuria remission in focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2018;13(3):414-421.

IgA nephropathy & proteinuria

Illustration of a stack of pages with one corner turned down.

Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402-2414.

Illustration of a stack of pages with one corner turned down.

Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177-3183.

Illustration of a stack of pages with one corner turned down.

Inker LA, Heerspink HJL, Tighiouart H, et al. Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis. Am J Kidney Dis. 2021;78(3):340-349.e1. doi:10.1053/j.ajkd.2021.03.007.

Illustration of a stack of pages with one corner turned down.

Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942-952.

Illustration of a stack of pages with one corner turned down.

Thompson A, Carroll K, Inker LA, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469-481.

Illustration of a stack of pages with one corner turned down.

Canney M, Barbour SJ, Zheng Y, et al. Quantifying duration of proteinuria remission and association with clinical outcome in IgA nephropathy. J Am Soc Nephrol. 2021;32(2):436-447. doi:10.1681/ASN.2020030349.

Sponsored satellite symposia

Illustration of a figure pointing to information on a whiteboard.

KIDNEY WEEK 2021

Title: Current Therapies and Treatment Responses in Primary Focal Segmental Glomerulosclerosis and IgA Nephropathy

Faculty: Dr. Michelle O'Shaughnessy, Dr. J. Ashley Jefferson, Dr. Jai Radhakrishnan

Illustration of a figure pointing to information on a whiteboard.

ERA-EDTA 2021 (Session ID: 1.1)

Title: Proteinuria Treatment Targets in FSGS and IgA Nephropathy

Faculty: Dr. Marcus Moeller, Prof. Frederick Tam, Prof. Loreto Gesualdo

Illustration of a figure pointing to information on a whiteboard.

IIGANN 2021

Title: The Journey to CKD in IgA Nephropathy: The Roles of Endothelin-1, Angiotensin II, and Proteinuria

Faculty: Prof. Jonathan Barratt, Prof. Matthias Barton, Prof. Jürgen Floege

Illustration of a figure pointing to information on a whiteboard.

WCN 2022

Title: The Link Between Endothelin-1, Angiotensin II, and Proteinuria in The Pathophysiology of CKD

Faculty: Prof. Jonathan Barratt, Dr. Donald Kohan, Dr. Ariela Benigni

CKD=chronic kidney disease; CME=continuing medical education; FSGS=focal segmental glomerulosclerosis; IgAN=immunoglobulin A nephropathy.

References:

1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int. 2021;100(4S):S1-S276. 2. Barbour SJ, et al. JAMA Intern Med. 2019;E1-E11.

Sign up for the latest news and updates on IgA nephropathy and FSGS

All fields are required.

Specialty

    I understand that by checking this box and clicking "Submit," I am submitting my contact information and may receive company and product information communications from Travere Therapeutics™. I also understand that my personal information provided will be processed by Travere Therapeutics™ to provide me access to the latest news and updates. For more information, review our privacy policies.

        Sign up successful

        Thank you for registering

        Back to the top